drugset / Trial / NCT03828123

Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis

NCT03828123 ↗

Phase 1/2 Completed 26 enrolled Bioinova, s.r.o. University Hospital, Motol · collab
NaSingle-groupOpen-labelTreatment

Summary

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease. Despite improved understanding of the mechanisms underlying ALS, the treatment remains essentially only supportive and focused on symptoms relief. Over the past few years, stem cell research has expanded greatly as a tool for developing new therapies to treat incurable diseases. Stem cell therapy has been shown as promising in several animal ALS models and human clinical trials.

Timeline

Start
2012-01
Primary completion
2017-08-18
Completion
2017-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Multipotent Mesenchymal Stromal Cells Unknown 1.5 ml Intrathecal
Subject Autologous Multipotent Mesenchymal Stromal Cells Unknown 1.5e+07 cells Intrathecal